Societal cost-of-illness in patients with borderline personality disorder one year before, during and after dialectical behavior therapy in routine outpatient care
Introduction
Borderline personality disorder (BPD) is a severe mental disorder that is characterized by high instability in affect regulation, impulse control, interpersonal relationships and self-image (Lieb, Zanarini, Schmahl, Linehan, & Bohus, 2004) and occurs in up to 2.7% of the general adult population (Trull, Jahng, Tomko, Wood, & Sher, 2010). There are many indications that BPD is associated with high cost-of-illness. From a societal perspective, cost-of-illness include all costs regardless of the payer and consist of direct costs related to medical and non-medical resource consumption and indirect costs due to loss of productivity. BPD patients use mental health services to a greater extent than patients with major depression (Bender et al., 2001, Bender et al., 2006) and patients with other personality disorders (Bender et al., 2001, Hörz et al., 2010). Thereby, on average, BPD patients are first hospitalized for psychiatric reasons at the age of 21 and first seek many other psychiatric and psychotherapeutic treatments between the age of 18 and 25 (Zanarini, Frankenburg, Khera, & Bleichmar, 2001), a critical period for professional development. Accordingly, there seems to be a strong relationship between BPD and poor occupational functioning. Skodol et al. (2002) found that in comparison to patients with major depression, a significantly higher proportion of BPD patients were disabled and significantly fewer were employed. Jackson and Burgess (2004) showed that among all personality disorders, BPD had the strongest association with lost days of role functioning. Furthermore, compared to remitted BPD patients, non-remitted BPD patients were more likely to have quitted or lost their jobs due to their impaired state of health (Frankenburg & Zanarini, 2004).
Despite these indications, BPD-related costs have rarely been investigated comprehensively. According to the only state-of-the-art cost-of-illness study assessing direct and indirect costs including 88 BPD patients seeking an outpatient psychotherapeutic treatment, BPD-related societal cost-of-illness in the Netherlands were substantial, amounting to €21120 (€16852)1 per BPD patient per year (Van Asselt, Dirksen, Arntz, & Severens, 2007). It is important to note that slightly more than 50% of total costs were indirect costs, mostly due to work disability, underlining the importance of completing comprehensive cost investigations. Additionally, several studies investigated BPD-related direct costs during the year preceding inpatient or outpatient psychotherapy. On average, these were €15088 in Germany (DM 24000; Jerschke, Meixner, Richter, & Bohus, 1998), €38771 (treatment group: US $44487, treatment-as-usual (TAU) group: US $52562; Bateman & Fonagy, 2003) and €16779 in Great Britain (treatment group: £7860, TAU group: £5240, each reported for a six-month period; Palmer et al., 2006) and €19978 in Australia (AUS $25526; Hall, Caleo, Stevenson, & Meares, 2001). A direct comparison between these results is impeded by a wide range of cost components included in the cost calculations in these investigations.
At the same time that BPD is associated with high costs and BPD patients are heavy users of mental health treatments that are seldom specifically designed for their disorder (Jobst, Hörz, Birkhofer, Martius, & Rentrop, 2010), there are several disorder-specific and clinically effective psychological treatments for BPD patients. Of these, Dialectical Behavior Therapy (DBT; Linehan, 1993a, Linehan, 1993b) has been studied most intensely in numerous randomized controlled trials (RCTs) and has the greatest empirical evidence concerning clinical efficacy (Stoffers et al., 2012). In particular, DBT was observed to be effective in reducing self-injurious and suicidal behavior, as well as in reducing psychiatric hospital days and emergency room visits (e.g. Koons et al., 2001, Linehan et al., 1991, McMain et al., 2009). Moreover, evidence indicates that these improvements can be maintained over a two-year follow-up period (McMain, Guimond, Streiner, Cardish, & Links, 2012).
Based on these results related to the clinical efficacy of DBT, one can reasonably assume that DBT also has great economic potential. Accordingly, Heard (2000) found that the total mean annual direct costs of BPD patients were €9210 (US $9889) lower when patients participated in outpatient DBT (€9178 respectively US $9856) compared to TAU (€18388 respectively US $19745) in the US. While treatment costs for outpatient psychotherapy were higher in the DBT group, these were offset by lower psychiatric inpatient and emergency room costs. Similarly, in an Australian trial by Pasieczny and Connor (2011), total direct costs per patient during a six month time interval were €8301 (AUS $12196) in the DBT group and €12335 (AUS $18123) in the TAU condition, resulting in cost savings of €4034 (AUS $ 5927) that again were primarily due to significantly lower inpatient costs. In contrast to these findings, in a sample of self-harming patients with any personality disorder diagnosis, total mean annual direct costs in the DBT group (€6310 respectively £5685) exceeded those in the TAU group (€4167 respectively £3754) by €2143 (£1931; Priebe, Bhatti, & Barn, 2012). Further, Brazier et al. (2006) undertook economic evaluations of four RCTs that had investigated the efficacy of DBT. Total direct costs from the governmental perspective were estimated on the basis of data from the RCTs and a cost regression model. Whereas the estimated total mean annual direct costs of patients treated with DBT and TAU were on a comparable scale in two studies (DBT: €19941 respectively £15691, TAU: €21475 respectively £16898, Linehan et al., 1991; DBT: €22151 respectively £17430, TAU: €21231 respectively £16706, Van den Bosch, Verheul, Schippers, & Van den Brink, 2002), the direct costs in the DBT group were considerably higher than in the TAU group in one study (DBT: €29787 respectively £23439, TAU: €18828 respectively £14815, Koons et al., 2001) and lower in another study (DBT: €20007 respectively £15743, TAU: €24026 respectively £20985, Turner, 2000).
In the present study, we assessed from the societal perspective the BPD-related cost-of-illness in a German sample of BPD patients in the 12 months prior to inclusion in a one-year outpatient DBT program. We further investigated BPD-related societal cost-of-illness during that specific year of outpatient DBT administered in the regular health-care system in the city of Berlin and during the following year. Following the results of Heard (2000) and Pasieczny and Connor (2011), we hypothesized that mostly due to the reduction of BPD-related inpatient treatment, the overall societal cost-of-illness during the DBT treatment year are lower than those in the year preceding DBT treatment. Also, in accordance with the findings of McMain et al. (2012), we expected that the presumed cost reduction is maintained during the follow-up year.
Section snippets
Materials and methods
The present investigation was conducted as part of a Berlin-wide treatment study (“Berliner Borderline Versorgungsstudie”; abbr.: BBV) evaluating the effectiveness of DBT in a naturalistic setting on the basis of a pre-post design with follow-up assessments. BBV was conducted at Charité-Universitätsmedizin Berlin and approved by the Charité's ethics committee. The methodology of this trial has been described in detail elsewhere (Stiglmayr et al., in revision).
Study participants
Socio-demographic and clinical characteristics at the time of study inclusion for the 47 patients who completed DBT treatment are shown in Table 2. Additionally, THI-data (average amount of BPD-related hospital and outpatient psychotherapeutic treatment utilization in the ten years prior to study inclusion) are presented (in Table 2).
Resource consumption and productivity loss
In Table 3, the mean annual amount of BPD-related resource consumption and mean annual amount of productivity loss during the three assessment periods is reported.
Main findings
In the present study, we assessed societal cost-of-illness in a German sample of BPD patients during three one-year periods: the year preceding outpatient DBT, the year of outpatient DBT in routine care and the follow-up year. Four major findings emerge from our study.
First, BPD poses a high economic burden that exceeds that of many other mental disorders. In the present study, BPD-related total societal cost-of-illness amounted to €28026 per patient during the year preceding DBT treatment,
Acknowledgments
We are grateful to all patients, therapists and research assistants (Friederike Horstmann, Lars Jensen, Sara Matthies, Suzan Monz, Heidi Päpke and Anke Rauch) who took part in this trial. We thank our colleagues on the Berliner Borderline Versorgungsstudie Jeanette Meißner, Doreen Spretz, Julia Stecher-Mohr, Christiane Steffens for assistance in conducting the study. We thank Claudia Dambacher, Dieter Gieb and Sara Matthies for their assistance in calculating (unit) costs. We thank Christian
References (66)
- et al.
Effectiveness of inpatient dialectical behavioral therapy for borderline personality disorder: a controlled trial
Behaviour Research and Therapy
(2004) - et al.
Efficacy of dialectical behavior therapy in women veterans with borderline personality disorder
Behavior Therapy
(2001) - et al.
Borderline personality disorder
Lancet
(2004) - et al.
The effectiveness of dialectical behaviour therapy in routine public mental health settings: an Australian controlled trial
Behaviour Research and Therapy
(2011) Naturalistic evaluation of dialectical behavioral-orientated treatment for borderline personality disorder
Cognitive and Behavioral Practice
(2000)- et al.
The cost of borderline personality disorder: societal cost of illness in BPD-patients
European Psychiatry
(2007) - et al.
Difficulties in calculating productivity costs: work disability associated with borderline personality disorder
Value in Health
(2008) - et al.
Dialectical behavior therapy of borderline patients with and without substance use problems. Implementation and long-term effects
Addictive Behaviors
(2002) - et al.
Treatment histories of borderline inpatients
Comprehensive Psychiatry
(2001) Diagnostic and statistical manual of mental disorders
(2000)
Cost of anxiety disorders in Europe
European Journal of Neurology
Health service utilization costs for borderline personality disorder patients treated with psychoanalytically oriented partial hospitalization versus general psychiatric care
American Journal of Psychiatry
Treatment utilization by patients with personality disorders
American Journal of Psychiatry
Prospective assessment of treatment use by patients with personality disorders
Psychiatric Services
Dialectical behaviour therapy for post-traumatic stress disorder after childhood sexual abuse in patients with and without borderline personality disorder: a randomized controlled trial
Psychotherapy and Psychosomatics
Psychological therapies including dialectical behaviour therapy for borderline personality disorder: a systematic review and preliminary economic evaluation
Health Technology Assessment
Psychiatrie im Bundesvergleich. Auswertung der Budgetvereinbarungen 2009 sowie weiterer Kennziffern der psychiatrischen Krankenhäuser aus dem Bundesland als interner Krankenhausvergleich gem. § 5 BPflV
Psychiatric inpatient expenditures and public health insurance programs: analysis of a national database covering the entire South Korean population
BMC Health Services Research
Borderline personality disorder: health service use and social functioning among a national household population
Psychological Medicine
Recovery from disability for individuals with borderline personality disorder: a feasibility trial of DBT-Aces
Psychiatric Services
Das Skillstraining und die poststationäre Effektivität der stationären Dialektisch-Behavioralen Therapie (DBT) nach sechs Monaten
Psychotherapie Psychosomatik·Medizinische Psychologie
A second labour market? Vocational rehabilitation and work integration of chronically mentally ill people in Germany
Acta Psychiatrica Scandinavica
HICP-inflation rate. Annual average rate of change (%)
Structured clinical interview for DSM-IV Axis II personality disorders (SCID-II)
Structured clinical interview for DSM-IV-TR Axis I disorders, research Version, Patient Edition (SCID-I/P)
The association between borderline personality disorder and chronic medical illnesses, poor health-related lifestyle choices, and costly forms of health care utilization
Journal of Clinical Psychiatry
Ten-year course of borderline personality disorder. Psychopathology and function from the collaborative longitudinal personality disorder study
Archives of General Psychiatry
An economic analysis of psychotherapy for borderline personality disorder patients
The Journal of Mental Health Policy Economics
Cost-effectiveness of dialectical behavior therapy for borderline personality disorder
Dissertation Abstracts International Section B: Sciences and Engineering
Barriers to implementing the clinical guideline on borderline personality disorder in the Netherlands
Psychiatric Services
What is meant by intention to treat analysis? Survey of published randomized controlled trials
British Medical Journey
Ten-year use of mental health services by patients with borderline personality disorder and with other axis II disorders
Psychiatric Services
Personality disorders in the community: results from the Australian national survey of mental health and well-being part III. Relationships between specific type of personality disorder, axis 1 mental disorder and physical conditions with disability and health consultations
Social Psychiatry and Psychiatric Epidemiology
Cited by (64)
Building a Life Worth Living During a Pandemic and Beyond: Adaptations of Comprehensive DBT to COVID-19
2021, Cognitive and Behavioral PracticeEmergency psychiatric management of borderline personality disorder: Towards an articulation of modalities for personalised integrative care
2020, EncephaleCitation Excerpt :These differences should be considered in relation to the GDP per capita and the cost of the hospital day per country. Among these studies, some have also taken into account indirect costs (loss of productivity, job loss, suicide, etc.) to establish the total annual cost per person to society: 11,300 € in Spain [58], 21,100 € in the Netherlands [59], 28,000 € in Germany [60]. These figures show that health costs account for 23% to 54% of the total cost to society.
Societal costs of personality disorders among treatment-seeking patients in Norway: the relative contribution of specific DSM-5 categories
2024, European Archives of Psychiatry and Clinical NeurosciencePlasma Endocannabinoid Levels in Patients with Borderline Personality Disorder and Healthy Controls
2023, International Journal of Molecular Sciences